AJANTPHARM \u2014 Recent Activity

India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs

Novo Nordisk's semaglutide patent expires March 20 as Indian drugmakers prepare lower-cost versions and hospitals expand obesity clinics.

Click to open →

Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Ajanta Pharma Ltd (BOM:532331) reports a robust 20% revenue increase in Q3, driven by significant growth in the US generics market and strategic initiatives for future expansion.

Click to open →

Inspira Global to buy stake in India's Burger King operator RBA for about $50.5 million

(Converts figures in paragraph 3 to billions of rupees, from crores of rupees) Jan 20 (Reuters) - Restaurant Brands Asia said on Tuesday that Inspira Global will acquire a controlling stake in the

Click to open →

Everstone to sell stake in Restaurant Brands Asia – report

The family office of the founders of Ajanta Pharma in India may inject up to Rs8bn ($88m) into RBA.

Click to open →

Everstone to sell stake in India's Burger King operator Restaurant Brands Asia, sources say

By Aditya Kalra, Yantoultra Ngui and Vibhuti Sharma NEW DELHI/SINGAPORE, Jan 19 (Reuters) - Private equity firm Everstone will sell its entire 11.26% stake in Burger King's India and Indonesia

Click to open →

Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Ajanta Pharma Ltd (BOM:532331) reports robust revenue growth and strategic product launches, despite facing forex losses and increased personnel costs.

Click to open →

Ajanta Pharma Ltd (BOM:532331) Q4 2025 Earnings Call Highlights: Strong Growth in Branded ...

Ajanta Pharma Ltd (BOM:532331) reports robust revenue growth driven by strategic expansions, despite challenges in the Africa Institution business.

Click to open →